It is a pharma private limited company based in Malegaon, Maharashtra, India, established in 2022.
2022 | Malegaon, Maharashtra, India | ActiveMannitab Pharma Specialities Private Limited, a active private limited company, was established on 02 May 2022 in Malegaon, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24290MH2022PTC381884. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹1.50 M and a paid-up capital of ₹0.30 M.
Employing 14 professional, Its leadership includes Rushabh Anilkumar Lodha (Director), Suk Gu Kim (Director), Stephen Kane Latreille (Director). Past directors included Jason Alexander Payant, Stephen Kane Latreille, Vijaykumar Bhagchand Lodha. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Lodha Bhuvan, Post Box No. 31 Malegaon, Malegaon, Maharashtra, 423203.
U24290MH2022PTC381884
381884
02 May 2022
₹1.50 M
₹0.30 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Mannitab Pharma Specialities Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rushabh Anilkumar Lodha | Director | 02 May 2022 | Current |
| Suk Gu Kim | Director | 01 Dec 2022 | Current |
| Stephen Kane Latreille | Director | 26 Aug 2024 | Current |
| Dineshkumar Bhagchand Lodha | Director | 02 May 2022 | Current |
| Sriprakash Krishnan | Director | 01 Dec 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 20 Aug 2024 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Director | 01 Dec 2022 | Past |
| Pramod Abcsdd | Director | 01 Dec 2022 | Past |
| Pramod Abcsdd | Director | 01 Dec 2022 | Past |
| Pramod Abcsdd | Director | 01 Dec 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Mannitab Pharma Specialities Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2023, Mannitab Pharma Specialities had a promoter holding of 35.00% and a public holding of 65.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Mannitab Pharma Specialities has a workforce of 14 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Mannitab Pharma Specialities, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mannitab Pharma Specialities's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Mannitab Pharma Specialities Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Stephen Kane Latreille was appointed as a Director was appointed as a Director on 26 Aug 2024 & has been associated with this company since 1 year 3 months . was recorded as a recent event.
The activity Mannitab Pharma Specialities Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was completed.
The activity Suk Gu Kim was appointed as a Director was appointed as a Director on 01 Dec 2022 & has been associated with this company since 3 years . was completed.
Progress on Sriprakash Krishnan was appointed as a Director was appointed as a Director on 01 Dec 2022 & has been associated with this company since 3 years . was documented.
The activity Rushabh Anilkumar Lodha was appointed as a Director was appointed as a Director on 02 May 2022 & has been associated with this company since 3 years 7 months . was completed.
The CIN of Mannitab Pharma Specialities Private Limited is U24290MH2022PTC381884.
Mannitab Pharma Specialities Private Limited is headquartered at Lodha Bhuvan, Post Box No. 31 Malegaon, Malegaon, Maharashtra, 423203.
Mannitab Pharma Specialities Private Limited was incorporated on 02 May 2022.
The current directors of Mannitab Pharma Specialities Private Limited are
The primary industry of Mannitab Pharma Specialities Private Limited is Manufacturing.
Mannitab Pharma Specialities Private Limited is unlisted.
The authorized capital of Mannitab Pharma Specialities Private Limited is ₹1.50 M, and the paid-up capital is ₹0.30 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX